Long-term follow-up of psilocybin-facilitated smoking cessation.
Long-term follow-up of psilocybin-facilitated smoking cessation.
复制标题
DOI：
10.3109/00952990.2016.1170135
复制
发表时间：
2017-01
期刊：
影响因子：
--
通讯作者：
Griffiths RR
中科院分区：
文献类型：
--
作者：
Johnson MW;Garcia-Romeu A;Griffiths RR
最近的一项开放标签试点研究（N=15）发现，两到三个中等到高剂量（20和30 mg/70 kg）的5-羟色胺2A受体激动剂裸盖菇素，结合认知行为疗法（CBT）戒烟，导致6个月的戒烟率大大高于通常观察到的其他药物或CBT单独。评估裸盖菇素促进戒烟计划在裸盖菇素给药后≥12个月的长期效果。本报告描述了既往初探性研究在≥12个月时经生物学验证的戒烟结局，以及裸盖菇素主观效应的相关数据。所有15名参与者均完成了12个月的随访，12名（80%）参与者返回接受长期（≥16个月）随访，目标戒烟日期（即，第一次裸盖菇素治疗）和长期随访。在12个月的随访中，10名参与者（67%）被证实戒烟。在长期随访中，9名参与者（60%）被证实戒烟。在12个月的随访中，13名参与者（86.7%）将他们的裸盖菇素经历评为他们生活中最有意义和精神意义的5种经历之一。这些结果表明，在结构化的治疗方案的背景下，裸盖菇素在促进长期戒烟方面具有相当大的前景。目前的研究增加了最近和历史的证据，表明使用经典迷幻药治疗成瘾的成功率很高。进一步的研究调查psilocybin促进物质使用障碍的治疗是必要的。
A recent open-label pilot study (N=15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16 – 57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the 5 most personally meaningful and spiritually significant experiences of their lives. These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.
登录
查看更多内容
DOI：
10.1177/0269881114548296
发表时间：
2014-11
期刊：
Journal of psychopharmacology (Oxford, England)
影响因子：
--
作者：
Johnson MW;Garcia-Romeu A;Cosimano MP;Griffiths RR
通讯作者：
Griffiths RR
影响因子：
3.4
作者：
Piedmont, RL
通讯作者：
Piedmont, RL
DOI：
10.1111/j.1530-0277.2007.00499.x
发表时间：
2007-10-01
影响因子：
3.2
作者：
Zemore, Sarah E.
通讯作者：
Zemore, Sarah E.
DOI：
10.1177/0269881111420188
发表时间：
2011-11
期刊：
Journal of psychopharmacology (Oxford, England)
影响因子：
--
作者：
MacLean KA;Johnson MW;Griffiths RR
通讯作者：
Griffiths RR
影响因子：
4.1
作者：
Griffiths, R. R.;Richards, W. A.;Jesse, R.
通讯作者：
Jesse, R.